Andros Pharmaceuticals Co.,Ltd
6917
Andros Pharmaceuticals Co., Ltd. operates as a biopharmaceutical enterprise,... Andros Pharmaceuticals Co., Ltd. operates as a biopharmaceutical enterprise, concentrating on the advancement of novel drug delivery platform technologies. Its development pipeline features APC101, a metered-dose, quick-drying, film-forming spray undergoing Phase IIa clinical investigation for the management of pain linked to post-herpetic neuralgia. Also in development is APC201, an innovative topical anesthetic formulation currently in Phase I/II trials for Osteoarthritis treatment, alongside an siRNA (small interfering RNA) compound functioning as an antisense oligonucleotide and DNA candidate. In the preclinical phase, the company is advancing APC310 and APC501, both intended as anesthetics for intravenous catheter insertion and venipuncture. Another preclinical asset, APC401, is a specialized emulsified solution targeting post-surgical pain relief. Beyond its developmental programs, Andros Pharmaceuticals also provides LALP cream for dermal analgesic use, iMinos solution for treating Alopecia Androgenetica, and T4 endonuclease V. Established in 2008, the firm maintains its headquarters in Zhubei, Taiwan.
